We're here to help. At Axol, we've spent more than a decade at the forefront of iPSC technology, adding to our bank of expertise in using iPSC-derived cells for drug discovery and research. Our straightforward workflows and simple to read protocols ensure you get the best from your cells, and we are always on hand to support you in achieving your goals.
Human iPSC-derived microglia are made by differentiating iPSCs from reprogrammed donor blood samples. They retain the phenotypic characteristics of the donor, producing a more human-relevant model system which opens up exciting applications of disease-derived microglia to test potential therapies in specific human disease models.
Our Scientific Group Leader, Jessica Tilman PhD., is deeply involved in both microglia based product development and the delivery of service projects. Jessica works in the cellular science group, and regularly participates in custom service projects, testing compounds on healthy and disease lines for disease specific phenotypes.
Jessica is happy to share her hard-won experience of working with microglia - here are her top tips:
1. Microglia are easily activated, so if you are replating, rest time is recommended before using them for assays.
2. Allow 7 days from thaw before using cells, and ensure the thawing process is as quick as possible to avoid loss of viability
3. For best results, seed cells directly onto a plate that is assay ready
Click here to read the Cryopreserved Mature Microglia User Guide : https://hubs.la/Q02KPPDV0
Or click here to watch the Tech Clinic: https://hubs.la/Q02KPPKw0
If you would like to use axoCells microglia to develop human-relevant models for drug discovery and research, contact us at operations@axolbio.com
#iPSCs #microglia #DrugDiscovery #StemCells #biopharma
